Figures
![Figure 1.](/tables/jocmr2851w-g001.jpg)
Figure 1. Flow diagram for meta-analysis. Overview of process used to identify studies suitable for inclusion in the meta-analysis.
![Figure 2.](/tables/jocmr2851w-g002.jpg)
Figure 2. Forest plot of all-cause mortality with ARA use in HF. Eight trials reported all-cause mortality rates with ARA use in HF patients compared to controls.
![Figure 3.](/tables/jocmr2851w-g003.jpg)
Figure 3. The forest plot of all-cause mortality with ARA use has been subdivided according to HF type.
![Figure 4.](/tables/jocmr2851w-g004.jpg)
Figure 4. The forest plot of all-cause mortality has been subdivided according to ARA type (whether non-selective or selective).
![Figure 5.](/tables/jocmr2851w-g005.jpg)
Figure 5. Forest plot of hospitalizations from cardiovascular cause with ARA use in HF. Ten trials reported cardiovascular hospitalization rates with ARA use in HF patients compared to controls.
![Figure 6.](/tables/jocmr2851w-g006.jpg)
Figure 6. The forest plot of cardiovascular hospitalizations has been subdivided according to HF type.
![Figure 7.](/tables/jocmr2851w-g007.jpg)
Figure 7. The forest plot of cardiovascular hospitalizations has been subdivided according to ARA type (whether non-selective or selective).
![Figure 8.](/tables/jocmr2851w-g008.jpg)
Figure 8. Forest plot of hyperkalemia with ARA use in HF. Fifteen trials reported hyperkalemia rates with ARA use in HF patients compared to controls.
![Figure 9.](/tables/jocmr2851w-g009.jpg)
Figure 9. The forest plot of hyperkalemia has been subdivided according to ARA type (whether non-selective or selective).
![Figure 10.](/tables/jocmr2851w-g010.jpg)
Figure 10. Forest plot of gynecomastia with ARA use in HF. Eight trials reported gynecomastia rates with ARA use in HF patients compared to controls.
![Figure 11.](/tables/jocmr2851w-g011.jpg)
Figure 11. The forest plot of gynecomastia has been subdivided according to ARA type (whether non-selective or selective).